Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the safety and efficacy of individually adjusted oral doses of runcaciguat in subjects with a clinical diagnosis of chronic renal failure with diabetes and / or hypertension.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BAYER AG
- Phase: II
- Execution start: 18/05/2020
- End of execution: 12/09/2021
- PI: JUAN DIEGO MEDIAVILLA GARCIA